Anavex Life Sciences Corporation (AVXL)

What is a realistic buyout share price?
$10 bucks?? Maybe

I remember the good old day when $1250 was the dream for many Anavex longs.

If they weren’t in talks with a company before, it could be some time before we hear of anything regarding a partner, merger, etc.  Any thoughts as to what phase we could be in? Preliminary due diligence, negotiations, etc. 

I continue to believe Dr. K. has been hired as interim CEO to clean up Missling’s mess and sell the company. I don’t think Dr. K. nor anybody else still at Anavex has the stomach to restart the company. I wouldn’t. What you posted makes sense if you believe as I do that a merger or sale is coming.

My previous hypothesis to explain the utter silence is that the board and Missling are lawyered up and fighting it out. However, I believe there would have been disclosure by now if lawsuits had been filed. The fact that no announcement regarding litigation had been made by now suggests that a coming merger or sale better explains the silence.

I hope so. There’s no way they can start a major trial with the skeleton crew they have in place right now. There’s no telling how many of the other 40 plus employees got laid off. There’s no work for them to do. Who would want to partner or trust us to run a trial in our current state? Yes, we have money and we could hire, but it would take some time to find the right people and get them up to speed. At this point I’d more than welcome a buyout. 

Only when it isn't real and positive. I wish the statistics wasn't in my favour,

And here you are instantly to refute anything positive. No surprise.

Anavex have had many silent periods in between which sweet fa happened. Each with silly theories just like your's

The smartest $AVXL insider sale ever was this one by: Boenisch Sandra valued at $4,422,444. About the same time that I sold the lion share of my holdings. Not having the trading skills of a fireman, I did buy a small number of shares back later at far too high prices - but all good at a generous 75% accuracy.

Companies often enter a silent period during merger or acquisition talks to limit public disclosure and reduce market speculation.
Wikipedia wakeforestlawreview.com
Silent Period in Mergers and Acquisitions
Definition and Purpose
Companies often enter a silent period during merger or acquisition discussions. This period is designed to limit public disclosure and reduce market speculation about the deal. By maintaining silence, companies can manage information flow and avoid unnecessary volatility in their stock prices.
Key Reasons for a Silent Period
Limit Public Disclosure: Prevents leaks of sensitive information that could affect negotiations.
Reduce Market Speculation: Minimizes rumors and speculation that could lead to stock price fluctuations.
Focus on Negotiations: Allows both parties to concentrate on the details of the deal without external pressures.
Typical Duration
The duration of a silent period can vary based on the complexity of the negotiations and regulatory requirements. It generally lasts until a formal announcement is made or until the deal is finalized.
In summary, entering a silent period is a common practice for companies engaged in merger or acquisition talks to ensure a smooth negotiation process and protect their interests.

If a Company wanted the Science but not Dr. Missling they might have to find a way to remove him.

I know this is speculation and not the verifiable information that is constantly presented here.

How can someone be marginally competent? That’s like being a little bit pregnant. Either you’re competent or incompetent. Nothing in between.

Another psychology chart
https://images.squarespace-cdn.com/content/v1/59403b68ebbd1a0b70768e34/1505851226228-V9LERGTV7706WRAKYUF5/static1.squarespace.jpg?format=1500w

Probably despondency here

14 stages of market psychology.
https://miro.medium.com/v2/resize:fit:1100/format:webp/1*-iKFWkSRqRYlxmde3Uo57A.jpeg
Where are we now.
https://schrts.co/aTbgVErT
If you are not a member here is a 5 year
https://schrts.co/dzrQCkBA
I believe we are in depression.

Missling needs to go away and enjoy the millions he made off the backs of Anavex shareholders.

As long as you are as excited as ever about your $AVXL investment, all is likely ok with a far too generous 75% chance.

Missling appears an incompetent or marginally competent guy with an advanced degree and with an accent. Still, there are loads of highly successful heads of companies that succeed enormously over time, but who cannot think their way out of a wet paper bag. The key is to be in the right industry and have a product that actually works. He could definitely run a corner convenience store provided it had decent food. Could he run an italian restaurant that was successful over time?
Not sure about that one.
Missiling was in the finance - advertising industry who sought to develop a biotech solution, and whose finance vehicle was publicly traded, meaning that it had the keys to the city; to wit, it could raise limitless money from the naive public even if it had no product. It is a tremendous job if you can get it.

Ultimately his attempts to find a successful product failed but you can hang around a very long time, making easy money, if you are in the finance-advertising industry and have the right to do limitless private offerings and money raises. It seems like a license to commit white collar crime which is lperfectly legal -- which is the funny part.

His developmental product never really had stunning results in any of its trials, but you get to lap up the easy money by advertising that it just takes patience.
It was a failed attempt, with a snazy website. So he was in the right industry, but without a product; it just took a long time for some of his backers to find this out. Which is why Richard Russell who was in the stock broker industry for about 65 years professionally, said that essentially the retail public should not be able to buy common stocks. It is a fool's game or a sucker play.
The one thing Missling did was raise money at opportune moments. He did not leave the company without money, which is how the advertsing - financing public venicles almost always meet their doom. The challenge however remains, how to find a product. I suspect that 95% of these small public companies, even if armed with over 100 million dollars in cash, eventually fail. But for the insiders, the product is the money raising capability. In a sense, once you get the listing, then you can tap into the public's money and then it is just a matter of advertising basically.

There’s probably a far too generous 75% chance that it was AI generated.

Reads like an AI generated fluff piece.

Past tense.
I’ve spent my career pushing for this kind of precision.
I would just suggest replacing "spent" with "wasted" and perhaps in the title.
3D Brain Map Breakthrough for Precision Medicine
Replace "Brain Map" with "Chess".

Yes. Quite entertaining.
https://www.linkedin.com/feed/update/urn:li:activity:7470142453950447616/

fmr.CEO Missling made 2 recent posts on Linkedin.

Who are these “suspicious KOLs” you claim have walked away?

I'm adjusting things - it used to be if this dogschitt of a stock went UP one dime it was an automatic SELL. Now, if it goes UP one nickel it's an automatic SELL. I imagine soon I'll have to adjust this to UP one penny. It's a pure steaming pile of dogschitt.

Several serious things happened, but I do not know what they gave as 'the cause'. The only reason I am here is that I still have some hope that the data is sound, and then there may be an opportunity. However, with all fired internal expertise, the silence and inactivity they are killing it quickly. With this damaged profile and with suspicious KOLs walking away it will not succeed.

Making definitive statements without any evidence to support them is not having your ear to the ground.

You seem to have your ear on the ground. Do you have any insight as to the cause for firing or if our data was compromised in any way?

Even if what you say about Terrie is true, none of us know the dynamic of their relationship. Missling could have pushed her down, dismissing her ideas and minimizing her role and value. She also could have been the loudest critic which the board realized in hindsight was correct. Either way, she can’t be worse than Missling and what better way for redemption than proving yourself as a first time ceo in a company that didn’t listen to you. Like you said, she has a decent background and most likely has some very good connections as well. If given a second chance, which I believe is happening right now, they are surely moving with the utmost care and diligence. 

She was expelled from the management team, but stayed as an advisor, only to be paid per real hours of work. After the failure with EMA several people spoke up against Missling and he needed to be replaced also for other reasons. The board has no clue how to develop a drug and bring it to the market. She was familiar with the company, knew a few people and seemed to have a decent background. Not being in the camp of Missling, helped her as well, because they still need to fight him out of the board.

That has been my publicly-stated view. IMO, Kellmeyer is there to clean up Missling’s mess and sell the company or merge it into a stronger company. The employees and directors want to move on with their lives and not drag this out for years to come with no guarantee of success. I think the majority of shareholders feel the same way.

“Missling kicked her out because of inactivity and several insiders confirm that.”

More fiction. Show us the evidence or retract your comment.

If Missling kicked her out for her incompetence, how did she rise to the top to get rid of Missling. Why didn't Leitke take over? I understand his lack of approvals might be a reason for cause, but to put someone in charge who never measured up is not making any sense. Looks more like a battle for control of company.

One AVXL option that cannot be discounted is the prospect of a buyout taking place.
As no one knows the exact reason for the prolonged silence, ongoing buyout negotiations are as reasonable an explanation as any.

One AVXL option that cannot be discounted is the prospect of a buyout taking place.
As no one knows the exact reason for the prolonged silence, ongoing buyout negotiations are as reasonable an explanation as any.

ACCES-AD was Missling's pet-project. He promised to do a separate trial with many biomarker and imaging endpoints as part of this project and was thus invited to join. Doing 2 new trials in AD was always unrealistic considering the finances, and with him, prof. Liedtke and others gone there is nobody to work with this group and collaboration will stop soon. There was a meeting in Germany last week with nobody present from Anavex. They are losing credibility very quickly.
Terrie Kellmeyer has been Anavex's senior vice-president clin dev and reg affairs for several years. A key member of the management team, but has anyone ever seen her at congresses, presentations or at discussions with regulatory affairs? Normally, at key congresses like CTAD and AAIC these people have some presence, meet KOL's and their team. Missling kicked her out because of inactivity and several insiders confirm that. Do your homework.

"Misery loves company" so I'm sure I share it with every other shareholder.

I have confidence that she will soon put us all out of your misery 🤣

Don't worry, Miss Communication is now in charge!

That ChatGPT answer is not useful.

We don’t know that there are anyone at Anavex who will participate and author presentations or what it would be about.

We don’t know much at this time other than the company appears dysfunctional.

From Chat gpgt- Based on the information available so far, yes, blarcamesine is still slated to be part of the European ACCESS-AD program, despite the leadership changes at Anavex. The ACCESS-AD consortium selected blarcamesine as one of the therapies to be evaluated in its five-year European Commission-funded Alzheimer’s initiative, and there has been no public announcement that it has been removed from the program.

What has changed is that Anavex’s board replaced CEO Christopher U. Missling and appointed Terrie Kellmeyer as interim CEO in May 2026. However, ACCESS-AD is a multi-party European research consortium, so participation is tied to the company and the program agreements rather than to a specific executive.

One caveat is that blarcamesine’s regulatory path in Europe has become more complicated. The European Medicines Agency recommended against approval in late 2025, and Anavex later withdrew its EU marketing application in March 2026 while the re-examination process was still ongoing.

So, at this point:

* ACCESS-AD participation: appears to remain in place.
* CEO change: does not automatically remove blarcamesine from ACCESS-AD.
* EU approval status: currently unresolved and more challenging after the withdrawn application.

From Chat gpgt- Based on the information available so far, yes, blarcamesine is still slated to be part of the European ACCESS-AD program, despite the leadership changes at Anavex. The ACCESS-AD consortium selected blarcamesine as one of the therapies to be evaluated in its five-year European Commission-funded Alzheimer’s initiative, and there has been no public announcement that it has been removed from the program.

What has changed is that Anavex’s board replaced CEO Christopher U. Missling and appointed Terrie Kellmeyer as interim CEO in May 2026. However, ACCESS-AD is a multi-party European research consortium, so participation is tied to the company and the program agreements rather than to a specific executive.

One caveat is that blarcamesine’s regulatory path in Europe has become more complicated. The European Medicines Agency recommended against approval in late 2025, and Anavex later withdrew its EU marketing application in March 2026 while the re-examination process was still ongoing.

So, at this point:

* ACCESS-AD participation: appears to remain in place.
* CEO change: does not automatically remove blarcamesine from ACCESS-AD.
* EU approval status: currently unresolved and more challenging after the withdrawn application.

This company is done . Maybe in 3 years after basically starting over we could see $3 again.
I am not trying to be funny, I am serious. Look at SAVA . Missling got fired after trying to bull sh t the EMA .
I wouldn’t waste anymore time here paying George and the guy that is on the other end. Extreme null sh t or something.
Unless you enjoy the daily company, it’s time to move on to a legit company I am afraid.
If we had what that journal claimed with all the signatures we would be sitting on some type of approval.
I believe Missling created or altered the report.
Crooked MFer

Negativity is primarily the funk we feel that we see extremely positive data that needs a longer and larger trial to get approval, delaying the approval for a minimum of three years.

Whether Anavex will even exist by then or be bought out is the unknown.

An investor’s best hope now is for a buyout rather than sitting on dead money for three plus years waiting for approval.

Only 17 posts before mine today...all posts were useless including mine. The only one worth reading was Mike's...putting up low after low. I should have sold at $3.

These submissions and agreements were done before everyone was fired. At this moment there is nobody to make such abstracts. I have several souces for this. Maybe they will hire new people, but they will need to get up to speed and familiar with all data and what has been presented and said before. A lot of damage was done to the company, also to the relations.
Alzheimer Europe is not really a scientific meeting for KOLs, AAIC in London and EAN in Geneva have much more weight.

Stop spreading FUD , Access Ad still using Blarcamesine


TTTav66 on ST


• ••
« SAVXL ACCESS-AD will have a strong presence at the Alzheimer Europe conference in October, with 3 presentations currently listed in the program. Notably, blarcamesine continues to be integrated directly into the core project overview abstract as an established, baseline asset:
"Prospective studies will evaluate
DMTs (such as anti-amyloid therapies and blarcamesine) in real-world practice, both alone and in combination with lifestyle interventions and nutritional strategies. Data on DMT safety, useability and clinical outcomes will be collected through InRAD's pan-European AD registry, with the EPND Hub enabling discovery, sharing and re-use of cohort data..."
It is highly encouraging to see confirmation of blarcamesine's ongoing, fundamental role within this important program. It will be interesting to see if new information about the planned studies will be shared at, or leading up to, this
+
conference.
Links to the ACCESS-AD conferencefica listings are included in the comments.

How do you know any of this? Seems made up to me. Evidence?